India, May 18 -- Design Therapeutics, Inc. (DSGN) shares fell 25.72 percent to $10.68, down $3.69 on Monday, despite the company reporting positive biomarker and clinical data from its ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 for Friedreich ataxia.
The stock is currently trading at $10.68, compared with a previous close of $14.37 on the Nasdaq. It opened at $15.94 and traded between $10.45 and $16.95 during the session, with volume reaching 3.81 million shares, well above the average daily volume of 397,863 shares.
The company said DT-216P2 increased frataxin expression and produced dose-dependent clinical improvements. In the highest dose cohort, patients showed an average 6.4-point improvement in the modified Friedreich's ...